Equity intelligence report • May 13, 2026
Biogen Inc. has reported a strong first quarter in 2026, with a notable 21% earnings beat, generating $2.48 billion in revenue despite adjusting its full-year profitability guidance downwards. Central to its growth strategy is the recent $5.6 billion acquisition of Apellis Pharmaceuticals, which aims to enhance Biogen's portfolio in immunology and rare diseases. While this deal received a mixed reaction from analysts regarding long-term revenue prospects, it is seen as key to bolstering Biogen's competitive edge in the evolving biotech landscape amidst rising market valuations and interest rate challenges.
Click a month on the chart to update the report below.
